UCLA has been certified to provide all FDA-approved CAR T-cell treatments, used to treat certain blood cancers. The certification enables UCLA to use this therapy for pediatric and young adults with B-cell precursor acute lymphoblastic leukemia, expanding on the initial program to treat adult patients with non-Hodgkin’s lymphoma. Expansion of the program furthers UCLA’s goal to be a destination of choice for patients receiving immunotherapy and other cellular therapies.
